^

News and Publications

Section Menu  

 

News Releases

Radiation oncology unites for policies that enhance patient access

Friday, September 12, 2025

As the world comes together this week for the first World Radiotherapy Awareness Day, the American Society for Radiation Oncology (ASTRO) and organizations across the cancer community are uniting in federal advocacy to support access to life-saving radiation therapy. “Radiation oncology is a lifeline for more than one million people with cancer in the US and millions more globally, and ASTRO is leading the charge to ensure these individuals have access to state-of-the-art care close to home,” said Howard Sandler, MD, FASTRO, Chair of the ASTRO Board of Directors. In official comments submitted today to Centers for Medicare & Medicaid Services (CMS) Administrator Mehmet Oz, ASTRO urged CMS to make important changes to the proposed 2026 Medicare physician and hospital outpatient payment rules released in July to ensure that radiation therapy services are reimbursed fairly, fostering equal access in communities nationwide.

ASTRO to showcase advances in radiation medicine and cancer research in 2025 Annual Meeting Press Program

Thursday, September 04, 2025

The American Society for Radiation Oncology (ASTRO) announced today the press program for its 2025 Annual Meeting this month in San Francisco. Researchers will discuss their findings in news briefings on September 29 and 30, and complimentary meeting registration is available for credentialed press. The field's most influential scientific forum, ASTRO's Annual Meeting will feature pivotal studies in radiation medicine for patients with cancer and other diseases.

American Society for Radiation Oncology (ASTRO) names Adam Greathouse as Director of Health Policy

Thursday, August 21, 2025

The American Society for Radiation Oncology (ASTRO), the leading medical society for physicians who treat patients with radiation therapy, recently promoted Adam Greathouse to Director of Health Policy. In his new role, Greathouse leads ASTRO’s advocacy efforts on priority health policy issues such as reducing prior authorization burdens that delay patients from starting cancer treatments and supporting reimbursement policies that preserve patient access to high-quality radiation oncology care.

Dr. Catheryn Yashar elected President of the American Society for Radiation Oncology (ASTRO)

Wednesday, July 23, 2025

The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-elect; Jonathan Strauss, MD, MBA, Secretary/Treasurer-elect; Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair; and David J. Carlson, PhD, FASTRO, Science Council Vice Chair. These officers will begin their terms September 30 at ASTRO’s 67th Annual Meeting in San Francisco.

Radiation oncology leaders named 2025 Fellows of the American Society Radiation Oncology

Wednesday, July 09, 2025

The American Society for Radiation Oncology (ASTRO) selected 43 members to receive the ASTRO Fellow (FASTRO) designation this year. This prestigious honor recognizes ASTRO members’ outstanding achievements and contributions to the Society, cancer research, education, patient care and the specialty. The new Fellows will be recognized at ASTRO’s 67th Annual Meeting in San Francisco on Tuesday, September 30.

ASTRO updates guideline on radiation therapy for high-grade diffuse glioma, the most common primary brain tumor in adults

Thursday, June 26, 2025

A from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy to treat adult patients with World Health Organization (WHO) grade 4 diffuse gliomas, a category that includes some of the most common and most aggressive primary brain tumors. The guideline, which replaces ASTRO’s 2016 guideline for glioblastoma, is published in Practical Radiation Oncology.

American Society for Radiation Oncology (ASTRO) names Karen Davis as Vice President of Business Development & Marketing

Wednesday, June 18, 2025

The American Society for Radiation Oncology (ASTRO), the leading organization for physicians who treat patients using radiation therapy, recently welcomed Karen Davis as its first Vice President of Business Development and Marketing. “Karen’s proven record of building high-impact partnerships and mobilizing resources for mission-driven organizations will help ASTRO accelerate initiatives that improve care for patients with cancer worldwide,” said ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO.

ASTRO applauds bipartisan reintroduction of legislation to reform prior authorization and protect patients

Wednesday, May 21, 2025

The American Society for Radiation Oncology (ASTRO) today applauded the reintroduction of bipartisan federal legislation to reform prior authorization processes under Medicare Advantage. The Improving Seniors’ Timely Access to Care Act of 2025 (S.1816, H.R.3514) addresses critical and pervasive barriers that impact timely access to lifesaving cancer treatments. “Prior authorization is a persistent and problematic thorn in the side of American health care. Patients and physicians — not insurance companies — should be at the center of treatment decisions,” said Howard M. Sandler, MD, FASTRO, Chair of the ASTRO Board of Directors.

ASTRO survey underscores damaging impact of continued Medicare cuts on cancer care; bipartisan ROCR Act offers solutions

Monday, May 19, 2025

New national survey data from the American Society for Radiation Oncology (ASTRO) show that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to the survey say that patient access will suffer under another cut, and seven in 10 say the impact will be significant. Radiation oncologists from across the country are on Capitol Hill today urging lawmakers to pass the bipartisan Radiation Oncology Case Rate (ROCR) Act before additional Medicare cuts are proposed. ROCR would stabilize Medicare payments, protect patient access and enhance cancer treatment outcomes by shifting from an outdated volume-based system to a value-based, bundled-payment model.

American Society for Radiation Oncology (ASTRO) to host Annual Meeting in San Francisco, September 27-October 1

Thursday, May 15, 2025

Registration opens today for the 67th American Society for Radiation Oncology (ASTRO) Annual Meeting, to be held at the Moscone Center in San Francisco, September 27 to October 1, 2025. Led by ASTRO President Sameer Keole, MD, FASTRO, the conference is centered around the theme of “Rediscovering Radiation Medicine and Exploring New Indications” and is expected to attract up to 10,000 oncologists, clinicians, researchers and other health care professionals from around the globe.

ASTRO emphasizes need for Medicare payment stability as Dr. Mehmet Oz confirmed as CMS Administrator

Friday, April 04, 2025

The American Society for Radiation Oncology (ASTRO) issued the following statement from Howard M. Sandler, MD, FASTRO, Chair of the ASTRO Board of Directors: “ASTRO congratulates Dr. Mehmet Oz on his confirmation as administrator of the Centers for Medicare and Medicaid Services (CMS). As cancer specialists devoted to improving patient outcomes, we look forward to working collaboratively with Dr. Oz and the CMS team on critical priorities including Medicare payment reform and prior authorization. Most Americans diagnosed with cancer are covered by Medicare, making CMS policies central to their access to timely, high-quality care.”

ROCR Act 2025: Congress takes step toward patient-centered, value-based cancer care with bipartisan plan

Friday, March 14, 2025

Today marks another pivotal milestone in the nation’s fight against cancer with the reintroduction of bipartisan federal legislation to transform Medicare reimbursement for radiation therapy. The Radiation Oncology Case Rate (ROCR) Value Based Payment Program Act of 2025, sponsored by Sens. Thom Tillis (R-N.C.) and Gary Peters (D-Mich.) and Reps. Brian Fitzpatrick (R-Pa.), Jimmy Panetta (D-Calif.), John Joyce, MD (R-Pa.) and Paul Tonko (D-N.Y.), would protect access to high quality cancer care and improve outcomes for patients nationwide, while generating savings for Medicare.

ASTRO issues its first clinical guideline on radiation therapy for anal cancer

Thursday, February 27, 2025

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma (SCC) of the anal canal and anal margin. The guideline, ASTRO’s first for anal cancer, is published in Practical Radiation Oncology.

New ASTRO survey finds that prior authorization delays lead to serious harm for people with cancer

Wednesday, December 04, 2024

A new nationwide survey of more than 750 radiation oncologists confirms that prior authorization harms people with cancer by causing treatment delays, abandoned treatments, hospitalizations and patient deaths. Findings also make clear that the problem of prior authorization is growing worse, with patients now experiencing longer radiation therapy treatment delays than during the height of the COVID-19 pandemic. Results of the survey, the latest in a series from the American Society for Radiation Oncology (ASTRO), reinforce the urgent need for Congress to pass prior authorization reform legislation and prevent further harm to people with cancer.

ASTRO issues update to clinical guideline on radiation therapy for rectal cancer

Monday, November 25, 2024

The American Society for Radiation Oncology (ASTRO) issued today an updated clinical guideline for physicians who use radiation therapy to treat patients with locally advanced rectal cancer. This update incorporates new data on patient selection and best practices from several practice-changing clinical trials published since the prior guideline was issued in 2020. The updated ASTRO guideline is published in Practical Radiation Oncology.

ASTRO celebrates contributions to radiation oncology with 2024 Gold Medals and other awards

Thursday, October 10, 2024

The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2024 Gold Medal awards and other high-profile honors during an awards ceremony at the 66th ASTRO Annual Meeting in Washington, DC. Photos of the awardees and the ceremony are available online.

Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer

Monday, September 30, 2024

People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival. Findings of the multi-institutional phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer

Monday, September 30, 2024

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%. De-intensified treatments involving a lower radiation dose and immunotherapy in place of chemotherapy did not perform as well as the more rigorous chemoradiation approach. Findings of the NRG Oncology HN005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer

Monday, September 30, 2024

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Spiritual themes, distrust may factor into Black patients’ reluctance to participate in cancer clinical trials

Monday, September 30, 2024

Spiritual beliefs and a historically-based distrust of clinical research may factor into Black patients’ decisions about whether to participate in cancer trials, according to surveys of patients treated at two Baltimore medical centers. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.This cross-sectional, descriptive study sought to shed light on what might be contributing to the growing underrepresentation of Black people in cancer trials and identify ways in which researchers might improve recruitment efforts so their findings can be generalizable to more diverse populations.

Post-mastectomy radiation therapy can be shortened by nearly half for patients planning breast reconstruction

Monday, September 30, 2024

An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. While radiation therapy following mastectomy to remove breast cancer is known to improve survival rates for certain patients who are at higher risk of recurrence, RT CHARM is the first multi-institutional international study to show that a shorter course of post-mastectomy radiation, combined with breast reconstruction, is safe and effective.

Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumors

Sunday, September 29, 2024

A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three large, phase III clinical trials. Recovery was more likely for people treated with conformal, or highly targeted, radiation techniques, compared to standard whole-brain treatment. The findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

People who experience side effects from cranial radiation therapy may recover full neurocognitive function within months

Sunday, September 29, 2024

A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may fully regain cognitive function, according to a pooled analysis of three large, phase III clinical trials. Recovery was more likely for people treated with conformal, or highly targeted, radiation techniques, compared to standard whole-brain treatment. The findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

ASTRO awards early career radiation oncology scientists with research grants and fellowships

Wednesday, September 18, 2024

The American Society for Radiation Oncology (ASTRO) today announced the recipients of its 2024 research grants and fellowships, including awards co-sponsored by the American Cancer Society (ACS), the LUNGevity Foundation, the Melanoma Research Alliance (MRA), the American Association of Physicists in Medicine (AAPM), the RTOG Foundation/NRG Oncology and AstraZeneca. Through these strategic partnerships, these awards recognize and support the outstanding efforts of early career researchers in the fields of radiation oncology and medical physics.

Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in Washington

Wednesday, September 04, 2024

The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast. Reporters can register to attend the briefings and join the Annual Meeting virtually or in person.

Dr. Neha Vapiwala voted President-elect of the American Society for Radiation Oncology (ASTRO)

Wednesday, July 17, 2024

The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors: Neha Vapiwala, MD, FASTRO, as President-elect; Jean Wright, MD, FASTRO, as Clinical Affairs & Quality Council Vice Chair; Andrea Ng, MD, MPH, FASTRO, as Education Council Vice Chair; Christopher Corso, MD, PhD, as Government Relations Council Vice Chair; and Malika Siker, MD, FASTRO, as Health Equity, Diversity and Inclusion (HEDI) Council Vice Chair. The officers will begin their terms October 1 at ASTRO’s 66th Annual Meeting in Washington, DC. 

ASTRO urges legislative action as reimbursement cuts continue in proposed FY25 MPFS

Thursday, July 11, 2024

The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M. Michalski, MD, MBA, FASTRO, Chair of the ASTRO Board of Directors, in response to the proposed 2025 Medicare Physician Fee Schedule (MPFS) released yesterday: “The declines in reimbursement for radiation therapy services for people with cancer under the Medicare physician fee schedule are disappointing. We are concerned that CMS continues to undervalue the impact of cost-effective radiation treatments for cancer and urge Congress to act on bipartisan radiation oncology payment reform legislation this year."

Radiation oncology leaders awarded ASTRO Fellow designation

Wednesday, July 10, 2024

The American Society for Radiation Oncology (ASTRO) selected 48 distinguished members to receive the ASTRO Fellow (FASTRO) designation for its 2024 class of Fellows. These physician leaders will be recognized at an awards ceremony in Washington, D.C. on Tuesday, October 1 during ASTRO’s 66th Annual Meeting. The ASTRO Fellows program recognizes individuals who have made substantial contributions to the Society and to the field of radiation oncology through research, education, patient care and service to the field.

Dr. Vivek S. Kavadi named CEO of the American Society for Radiation Oncology (ASTRO)

Thursday, June 20, 2024

The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search, Vivek S. Kavadi, MD, MBA, FASTRO will become CEO of the Society effective November 1, 2024. Dr. Kavadi, a radiation oncologist and ASTRO member since 1994, steps into the role from his current position as Chief Radiation Oncology Officer for The US Oncology Network. He will succeed Laura Thevenot, who previously announced her intent to retire after leading the organization since 2002.

ASTRO issues clinical guideline on radiation therapy for patients with HPV-related throat cancer

Tuesday, June 18, 2024

The American Society for Radiation Oncology (ASTRO) published today an updated clinical guideline that details best practices for using radiation therapy to treat patients who have oropharyngeal squamous cell carcinoma (OPSCC) caused by the human papillomavirus (HPV). Recommendations address radiation therapy as a standalone curative treatment or in combination with surgery and/or chemotherapy. The guideline is available as a free-access article in Practical Radiation Oncology, ASTRO’s clinical practice journal.

ASTRO applauds new bipartisan legislation to reform prior authorization for Medicare Advantage patients

Wednesday, June 12, 2024

The American Society for Radiation Oncology (ASTRO) applauded today’s introduction of bipartisan federal legislation to address critical flaws in the prior authorization process. The Improving Seniors’ Timely Access to Care Act of 2024, introduced by Senators Roger Marshall, MD (R-Kan.), Kyrsten Sinema (I-Ariz.), John Thune (R-S.D.) and Sherrod Brown (D-Ohio) and Representatives Mike Kelly (R-Pa.), Suzan DelBene (D-Wash.), Ami Bera, MD (D-Calif.) and Larry Bucshon, MD (R-Ind.), is an important step toward improving care delivery for people with cancer nationwide.

ASTRO clinical guideline on radiation therapy for bone metastases emphasizes patient-centered care

Thursday, May 23, 2024

The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details best practices for treating patients who have symptomatic bone metastases and ways to improve their quality of life. The guideline is available as a free access article in Practical Radiation Oncology, ASTRO's clinical practice journal.

American Society for Radiation Oncology (ASTRO) to host Annual Meeting in Washington, D.C., September 29-October 2

Thursday, May 16, 2024

Registration opens today for the American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting, which will be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 2, 2024. Led by ASTRO President Howard Sandler, MD, FASTRO, the conference is expected to attract up to 10,000 oncologists, clinicians, researchers and other health care professionals from around the globe.

Bipartisan bill to modernize radiation oncology reimbursement introduced in Congress

Wednesday, May 15, 2024

Today marks a significant milestone in cancer care with the introduction of bipartisan federal legislation that would revolutionize Medicare reimbursement for radiation therapy. The Radiation Oncology Case Rate (ROCR) Value-Based Payment Program Act of 2024, sponsored by Sen. Thom Tillis (R-N.C.) and by Reps. Brian Fitzpatrick (R-Pa.), Jimmy Panetta (D-Calif.), John Joyce, MD (R.Pa.) and Paul Tonko (D-N.Y.), would protect access to high value cancer treatments for patients across the country, enhance patient outcomes and reduce health disparities while generating savings for Medicare.

Noteworthy studies to be presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium

Thursday, February 29, 2024

Research on patient-centered treatment of head and neck cancers will be presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium, which takes place in Phoenix and online today through March 2.

2024 Multidisciplinary Head and Neck Cancers Symposium to be held in Phoenix and online Feb. 29 – Mar. 2

Wednesday, January 31, 2024

The 2024 Multidisciplinary Head and Neck Cancers Symposium will take place February 29 to March 2 in Phoenix and via livestream for virtual attendees. The meeting is cosponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Head and Neck Society (AHNS) and the Society for Immunotherapy of Cancer (SITC).

Radiation oncology physician groups unite to ensure patient access to cancer care

Tuesday, January 09, 2024

Today, the largest professional societies representing radiation oncology physicians in the United States announced a partnership with the goal of reforming radiation oncology Medicare payments to expand and enhance access to high quality care for people with cancer. Leaders of the American College of Radiation Oncology (ACRO), the American College of Radiology (ACR), the American Society for Radiation Oncology (ASTRO) and the American Society of Clinical Oncology (ASCO) stressed the need for a unified approach to create meaningful change on this critical issue.

American Society for Radiation Oncology (ASTRO) CEO Laura Thevenot announces 2024 retirement

Monday, January 08, 2024

The American Society for Radiation Oncology (ASTRO) today announced that CEO Laura Thevenot plans to retire at the end of 2024 after leading the organization since 2002. “It has been my privilege to work on behalf of our ASTRO members these past 22 years. Serving as ASTRO’s CEO has given me an opportunity to collaborate with the incredible members of our Board of Directors and volunteers to expand and enhance how we serve our members. In addition, I have been fortunate to work with a team of dedicated staff who are committed to our mission. ASTRO is thriving because of our volunteers’ and staff’s commitment to do the best possible work on many fronts to help our members and the patients they serve. I am deeply appreciative of our volunteers and members and will continue our focused efforts until I retire at the end of the year,” said Thevenot.

Copyright © 2025 American Society for Radiation Oncology